Journal Guide

Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology and drug abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology.One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and the pharmacokinetic effects of drugs. Recent research has shown the importance of examining the effects of sex and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse and the alleviation of pain.The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects.The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology and drug abuse.The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.Each year, the journal will recognize young investigators who are recipients of the Young Psychopharmacologist Award or the Best Dissertation Award, as well as midcareer and senior scientists who receive the Brady–Schuster Award from APA Division 28, Psychopharmacology and Substance Abuse. Awardees will be invited to submit a review paper based on their award-winning research.The journal may occasionally publish innovations in psychopharmacology that report a novel method, measure, or result. Commentary on the nature and implications of the innovation may be invited.The overall goal is to provide a forum for innovative clinical and preclinical research that advances our understanding of the behavioral and biological determinants of the effects of drugs.

Expert Opinion on Biological Therapy ranks #42 of 160 in the Biotechnology & Applied Microbiology category and #30 of 106 in the Medicine, Research & Experimental category in the 2009 ISI Journal Citation Reports.Expert Opinion on Biological Therapy (ISSN 1471-2598 [print], 1744-7682 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.The Editors welcome: * Reviews covering gene therapy and gene transfer technologies; therapeutic peptides and proteins; vaccines and antibodies; cell- and tissue-based therapies * Drug Evaluations reviewing the clinical data on a particular biological agent * Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practiceThe audience consists of scientists and managers in the healthcare and biopharmaceutical industry and others closely involved in the development of biological therapy for the treatment of human disease.

Expert Opinion on Drug Delivery ranks #32 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders * Technology Evaluations reviewing a particular drug delivery technologyThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.

Expert Opinion on Drug Discovery ranks #176 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology * Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug * Perspectives on topical issues with potential impact on the future of drug discoveryThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Orphan Drugs will be an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.

Expert Opinion on Therapeutic Patents ranks #3 of 13 in the Medicine, Legal category and #118 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. * Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area * Patent Evaluations examining the aims and chemical and biological claims of individual patents * Perspectives on issues relating to intellectual propertyThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D.

Expert Opinion on Therapeutic Targets ranks #53 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on recently identified novel molecular drug targets, providing expert opinion on the scope for future development and impact on drug discovery.The Editors welcome: * Reviews covering novel disease targets at the molecular level and their implications on future drug development * Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugsThe audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D.Read More: http://informahealthcare.com/page/Description?journalCode=ett.

Expert Review of Precision Medicine and Drug Development publishes original research and review articles covering the development and clinical application of medicine to be used in a personalized therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include:

• Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. 
• Clinical trials and case studies within personalized therapy and drug development. 
• Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment.
• Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. 
• Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.

Expert Review of Vaccines (ISSN 1476-0584) provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism. All articles are subject to rigorous peer-review.

F1000Research is an Open Research publishing platform for life scientists, offering immediate publication of articles and other research outputs without editorial bias. All articles benefit from transparent refereeing and the inclusion of all source data.